Cytokinetics, Incorporated

Total Valuation

Cytokinetics, Incorporated carries a market capitalization of 9.05B, placing it among publicly traded companies globally. Its enterprise value stands at 11.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Cytokinetics, Incorporated currently has 138.76M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 156.66, and the price-to-book ratio stands at -68.14.

Enterprise Valuation

Financial Position

Cytokinetics, Incorporated maintains a current ratio of 6.66, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -732.36, indicating conservative leverage, while an interest coverage ratio of -5.57 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Stock Price Statistics

Cytokinetics, Incorporated's stock has gained approximately 39.60453% over the past 52 weeks. The 50-day moving average sits at 79.19, while the 200-day moving average is 69.76.

Income Statement

Over the trailing twelve months, Cytokinetics, Incorporated generated 67.67M in revenue and converted that into -894.00M in net income, yielding earnings per share of -7.18. EBITDA reached -695.36M, while operating income came in at -707.91M.

Balance Sheet

Cytokinetics, Incorporated holds 1.17B in cash and equivalents against 1.27B in total debt, resulting in a net debt position of 891.82M. Total book value stands at -173.49M, with working capital of 1.03B providing operational flexibility.

Cash Flow

Cytokinetics, Incorporated produced -555.45M in operating cash flow over the past twelve months. After subtracting -25.26M in capital expenditures, free cash flow totaled -580.71M - equivalent to -4.67 per share.

Margins

Cytokinetics, Incorporated operates with a gross margin of -212.95, reflecting its pricing power and cost economics. The operating margin of -1,046.12 and net profit margin of -1,321.12 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Cytokinetics, Incorporated's most recent stock split took place on June 25, 2013 with a 6:1 split ratio.

Scores

Cytokinetics, Incorporated posts an Altman Z-Score of 0.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.